Jeevan Scientific Technology Limited has submitted a regulatory disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The Central Drugs Standard Control Organization (CDSCO) has granted approval for increasing the bed capacity at the company's existing Bioavailability/Bioequivalence (BA/BE) Study Centre. The approval increases the capacity from 132 beds and 06 ICU beds to 156 beds and 08 ICU beds.
The BA/BE Study Centre is located at Plot No. B-17, TIE Phase II, Balanagar, Hyderabad-500037, Telangana, India.
The approval was granted following the successful completion of a regulatory inspection conducted by CDSCO on June 24, 2026, and the company's application seeking enhancement of bed capacity at the facility.
The increased bed capacity is expected to strengthen the company's clinical research infrastructure, enhance operational capabilities, and enable undertaking a higher volume of Bioavailability/Bioequivalence studies, thereby supporting future business growth.
The company states it remains committed to maintaining the highest standards of quality, regulatory compliance, and patient safety in all its clinical research operations.
The disclosure was signed by Krishna Sainadh Kodati, Company Secretary & Compliance Officer, on August 01, 2026.